Phaseline

Targets › MESOTHELIN

MESOTHELIN: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Apr 2027.

Open in Phaseline: the race on MESOTHELIN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Memorial Sloan Kettering Cancer CenteriCasp9M28z T cells
Anti-mesothelin CAR-T cells with inducible caspase-9 safety switch
MESOTHELINPhase 1Malignant Pleural DiseaseApr 2027

Conditions

Malignant Pleural Disease (1)

Modalities

mixed (1)

Companies

Memorial Sloan Kettering Cancer Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.